Selurampanel
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H19N5O4S |
Molar mass | 377.418 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]
References
- ^ Faught, Edward (2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs. 23 (1): 107–113. doi:10.1517/13543784.2014.848854. ISSN 1354-3784.
- ^ Belcastro, Vincenzo; Verrotti, Alberto (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy": 183–199. doi:10.1007/978-3-319-12283-0_10.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Hanada, Takahisa (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Gomez-Mancilla B, Brand R, Jürgens TP, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia. 34 (2): 103–13. doi:10.1177/0333102413499648. PMID 23963355.